BRPI0515185A - combinação de compostos orgánicos - Google Patents

combinação de compostos orgánicos

Info

Publication number
BRPI0515185A
BRPI0515185A BRPI0515185-6A BRPI0515185A BRPI0515185A BR PI0515185 A BRPI0515185 A BR PI0515185A BR PI0515185 A BRPI0515185 A BR PI0515185A BR PI0515185 A BRPI0515185 A BR PI0515185A
Authority
BR
Brazil
Prior art keywords
disease
inhibitors
diseases
pharmaceutically acceptable
combination
Prior art date
Application number
BRPI0515185-6A
Other languages
English (en)
Inventor
William Maher
Michele Mercuri
Meenakshi Nevatia
Hong Chen
Pei-Ran Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35385557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0515185(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0515185A publication Critical patent/BRPI0515185A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

COMBINAçãO DE COMPOSTOS ORGáNICOS. A presente invenção refere-se a uma composição farmacêutica, compreendendo um agonista de PPAR, ou sais farmaceuticamente aceitáveis do mesmo, sozinho ou em combinação com no mínimo um ingrediente ativo selecionado entre o grupo consistindo em (i) compostos que aumentam o HDL; (ii) antidiabéticos; (iii) um agente anti-hipertensivo; (iv) modulador da absorção de colesterol; (v) miméticos e análogos de apo-A1; (vi) inibidores de refina; (vii) inibidores de trombina; (viii) inibidores de aldosterona; (ix) agonistas de GLP-1 (x) antagonistas de receptores de glucagon; (xi) antagonistas de receptores de canabinóide 1; (xii) agentes antiobesidade; e (xiii) inibidores da agregação plaquetária ou, em cada caso, um sal farmaceuticamente aceitável do mesmo; e opcionalmente um veículo farmaceuticamente aceitável. A composição farmacêutica pode ser empregada para o tratamento de adições (por exemplo, nicotina e cocaína), dislipidemia, hiperlipidemia, hipercolesteremia, aterosclerose, hipertrigliceridemia, falência cardíaca, enfarte do miocárdio, doenças vasculares, doenças cardiovasculares, derrame, claudicação intermitente, restenose depois de PCTA, hipertensão, obesidade inclusive redução do risco cardiovascular em pacientes obesos, inflamação, artrite, câncer inclusive câncer de mama, de cólon e de próstata, doença de Alzheimer, doenças de pele, doenças respiratórias, distúrbios oftálmicos, Dlls (doença intestinal irritável), doença de Crohn, hipofibrinólise, estado hipercoagulável, síndrome metabólica 1 cardiometabólica, proteína C-reativa elevada, aparecimento de microalbuminúria, redução da proteinúria, falência renal (diabetes melitus, não diabetes melitus), NASH (esteato hepatite não alcoólica) fígado gorduroso não alcoólico, eventos cardiovasculares em pacientes com proteína C-reativa elevada, demência vascular, psoríase, lesão por reperfusão de isquemia, asma, doença pulmonar obstrutiva crónica, eosinofilia, RA, hiper-responsividade das vias aéreas (HVA), doenças digestivas inflamatórias (por exemplo, colite ulcerativa) doenças de respostas inflamatórias induzidas por antígeno. Os compostos da presente invenção são particularmente úteis em mamíferos como agentes hipoglicêmicos para o tratamento e a prevenção de condições tais como diminuição da tolerância á glicose, hiperglicemia, resistência à insulina, diabetes tipo 1 e tipo 2 e Síndrome X. Também é contemplada a administração das combinações da presente invenção para a melhora do metabolismo cardíaco e cardioproteção em pacientes de transplante do coração, para facilitar a cessação ou redução do fumo e para prevenir ou tratar condições associadas com fumo.
BRPI0515185-6A 2004-09-09 2005-09-08 combinação de compostos orgánicos BRPI0515185A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60831004P 2004-09-09 2004-09-09
US60957704P 2004-09-14 2004-09-14
US68973805P 2005-06-10 2005-06-10
PCT/US2005/032224 WO2006029349A1 (en) 2004-09-09 2005-09-08 Combination of organic compounds

Publications (1)

Publication Number Publication Date
BRPI0515185A true BRPI0515185A (pt) 2008-07-22

Family

ID=35385557

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515185-6A BRPI0515185A (pt) 2004-09-09 2005-09-08 combinação de compostos orgánicos

Country Status (13)

Country Link
US (1) US20070299047A1 (pt)
EP (1) EP1791600A1 (pt)
JP (1) JP2008512486A (pt)
KR (1) KR20070106677A (pt)
AR (1) AR050631A1 (pt)
AU (1) AU2005282290B2 (pt)
BR (1) BRPI0515185A (pt)
CA (1) CA2578290A1 (pt)
GT (1) GT200500246A (pt)
MX (1) MX2007002879A (pt)
PE (1) PE20060594A1 (pt)
TW (1) TW200621220A (pt)
WO (1) WO2006029349A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
JP4708795B2 (ja) 2002-12-20 2011-06-22 ニコノヴァム エービー 物理的および化学的に安定なニコチン−含有粒状物質
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
CA2684059C (en) 2007-04-11 2016-07-12 Omeros Corporation Use of a ppary agonist, alone or in combination, for the treatment or prophylaxis of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
AU2013201888B2 (en) * 2007-04-11 2016-02-25 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
IE20070928A1 (en) * 2007-12-21 2009-09-30 Giuliani Int Ltd Multi target ligands
WO2009154230A1 (ja) * 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP5715070B2 (ja) 2009-02-16 2015-05-07 ノグラ ファーマ リミテッド アルキルアミド化合物およびその使用
MX2011009384A (es) 2009-03-11 2011-10-11 Omeros Corp Composiciones y metodos para profilaxis y tratamiento de adicciones.
WO2011100659A2 (en) * 2010-02-12 2011-08-18 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
CN107899012A (zh) 2011-01-11 2018-04-13 戴麦里克斯生物科学有限公司 联合疗法
WO2013071077A1 (en) 2011-11-09 2013-05-16 Cornell University The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies
CN104254327A (zh) 2012-02-09 2014-12-31 诺格拉制药有限公司 治疗纤维化的方法
EP3834888A4 (en) * 2018-08-10 2022-05-11 Servicio Andaluz De Salud AGENTS FOR THE TREATMENT OF ALCOHOL USE DISORDER
CN113825739A (zh) 2019-02-08 2021-12-21 诺格拉制药有限公司 制备3-(4’-氨基苯基)-2-甲氧基丙酸及其类似物和中间体的方法
WO2022117862A1 (en) 2020-12-03 2022-06-09 Delta 4 Gmbh Clopidogrel for use in the treatment of focal segmental glomerulosclerosis (fsgs)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
FR2530247B1 (fr) * 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
US6488961B1 (en) * 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
DE602004023080D1 (de) * 2003-05-20 2009-10-22 Novartis Ag N-acyl stickstoffheterocyclen als liganden von peroxisom-proliferator-aktivierten rezeptoren

Also Published As

Publication number Publication date
AU2005282290B2 (en) 2009-06-25
EP1791600A1 (en) 2007-06-06
AU2005282290A1 (en) 2006-03-16
TW200621220A (en) 2006-07-01
WO2006029349A1 (en) 2006-03-16
CA2578290A1 (en) 2006-03-16
JP2008512486A (ja) 2008-04-24
MX2007002879A (es) 2007-04-23
GT200500246A (es) 2006-04-17
KR20070106677A (ko) 2007-11-05
PE20060594A1 (es) 2006-08-18
US20070299047A1 (en) 2007-12-27
AR050631A1 (es) 2006-11-08

Similar Documents

Publication Publication Date Title
BRPI0515185A (pt) combinação de compostos orgánicos
Lippi et al. Current and emerging direct oral anticoagulants: state-of-the-art
Li et al. Obstructive sleep apnea syndrome and metabolic diseases
Qin et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats
Henderson et al. An exploratory open‐label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia
Chisholm et al. Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures
Bhoelan et al. Barium toxicity and the role of the potassium inward rectifier current
Santos-Gallego et al. Role of HDL in those with diabetes
CN1267098C (zh) 将脱碳乙氧基氯雷他定或其可药用盐用于制备治疗过敏性鼻炎的药物的用途
Radhakrishnan et al. Circulating levels of cytochrome c after resuscitation from cardiac arrest: a marker of mitochondrial injury and predictor of survival
CN100421659C (zh) 用于降低血浆脂蛋白(a)和心血管疾病危险因素的组合物和其制药用途
Alwaili et al. High-density lipoproteins and cardiovascular disease: 2010 update
Ratziu Novel pharmacotherapy options for NASH
Nseir et al. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review
CN102939089A (zh) 使用抗氧化剂炎症调节剂治疗肥胖症的方法
CN105307652A (zh) 非酒精性脂肪性肝病治疗剂
Klancic et al. High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties
Lanng et al. Gluco-metabolic effects of oral and intravenous alcohol administration in men
BRPI0412479A (pt) composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, métodos de tratamento e/ou prevenção de distúrbios lipìdicos (dislipidemia) associados ou não com a resistência à insulina, e de aterosclerose, e, métodos de tratamento e/ou profilaxia de doença cardiovascular, de hipercolesterolemia, condições associadas com a necessidade de se melhorar o transporte de colesterol reverso, de se diminuir a absorção de colesterol no intestino, de se aumentar os nìveis de colesterol hdl, de se diminuir os nìveis de colesterol ldl, de condições inflamatórias, de mal de alzheimer, de arteriosclerose, de diabetes tipo 2, e de condições associadas com a necessidade de se melhorar a função de hdl, e, composição farmacêutica
Rupprecht et al. Self-administered nicotine increases fat metabolism and suppresses weight gain in male rats
Yang et al. Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment
TW200503691A (en) Therapeutic agents
Xie et al. Role of endogenous glucagon‐like peptide‐1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes
Eldor et al. Oral insulin (ORMD‐0801) in type 2 diabetes mellitus: A dose‐finding 12‐week randomized placebo‐controlled study
Cimmino et al. High density lipoprotein cholesterol increasing therapy: the unmet cardiovascular need

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 5A E 6A ANUIDADES.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/00 (2006.01), A61P 25/30 (2006.01), A61P 9